市场推广经理(北京)
百奥泰生物制药股份有限公司
- 公司规模:500-1000人
- 公司性质:合资
- 公司行业:制药/生物工程
职位信息
- 发布日期:2019-08-09
- 工作地点:北京
- 招聘人数:1人
- 工作经验:2年经验
- 学历要求:招1人
- 语言要求:不限
- 职位月薪:20-100万/年
- 职位类别:市场/营销/拓展经理
职位描述
岗位职责:
- 深度了解区域市场,与RM讨论并制定有针对性的季度推广计划,跟进评估区域推广活动的执行(频率和质量),不断提升推广效率;
- 定期拜访KOL和区域讲者,完善大区层面推广活动;
- 与总监共访,辅导、落实产品策略执行和产品信息传递;
- 定期组织产品知识和策略学习,提高团队专业水准;
- 沟通、协调市场部项目的执行,及时提供反馈;
- 申请和报销跨区域或全国性学术会议、教育基金、企业基金等;
- 内外部销售会议及专家会议的筹备及召开,汇总并及时传递各类内外部信息;
- 严守诚信,保持真实透明,在过往的销售工作中无任何违反法律规定的行为发生。
任职条件:
- 有2年以上市场营销管理经验;有外企营销管理经验优先考虑;
- 参考过去两年销售业绩,达成率/增长率需达到或超过团队平均水平;
- 具有强烈的学习意愿和能力,勇于承担,执行力强;
- 具有团队合作共赢精神,擅长自我激励和高效沟通;
- 具备一定的战略思维和制定精准市场策略的能力。
备注:该岗位另有绩效奖励计划,我们热诚期待您的加入。
职能类别:市场/营销/拓展经理
关键字:市场推广
公司介绍
百奥泰生物制药股份有限公司(股票代码:688177)秉承“创新只为生命”的理念,致力于开发新一代创新药和生物类似药,用于治疗肿瘤、自身免疫性疾病、心血管疾病以及其它危及人类生命或健康的重大疾病。公司已推动五款候选药物进入后期临床试验,其中格乐立(阿达木单抗)已在中国获批用于治疗类风湿关节炎、强直性脊柱炎、银屑病、克罗恩病和葡萄膜炎。此外,公司另有多款主攻肿瘤和自身免疫性疾病的候选药物处于不同的临床开发阶段。公司始终以患者的福祉作为首要核心价值,通过创新研发为患者提供安全、有效、可负担的优质药物,以满足亟待解决的治疗需求。欲了解更多信息,请访问公司官网或关注我们的微信公众号“百奥泰”。
Bio-Thera?Solutions, Ltd.a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials, one of which, QLETLI, a biosimilar to?Humira?(adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis,?Crohn's disease or uveitis in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases.
Bio-Thera?Solutions, Ltd.a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials, one of which, QLETLI, a biosimilar to?Humira?(adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis,?Crohn's disease or uveitis in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases.
联系方式
- Email:bd@bio-thera.com
- 公司地址:广州科学城开源大道11号科技企业加速器A6幢5楼 (邮编:510530)